Compounds > alpha-aminopyridine
Page last updated: 2024-08-21

alpha-aminopyridine and Triple Negative Breast Neoplasms

alpha-aminopyridine has been researched along with Triple Negative Breast Neoplasms in 26 studies

Research

Studies (26)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's12 (46.15)24.3611
2020's14 (53.85)2.80

Authors

AuthorsStudies
Cao, J; Gong, C; Hu, X; Jin, J; Li, T; Meng, Y; Miao, H; Tao, Z; Wang, B; Wang, L; Zhang, J1
Feng, J; He, X; Ji, J; Li, G; Liu, B; Lv, J; Ma, J; Pan, G; Wang, W; Wang, X; Xie, M; Xu, Y; Zhang, Z1
Clarke, R; Goetz, MP; O'Sullivan, CC; Robertson, J1
Adeola, SA; Adu, OB; Ajayi, DC; Akinola, IA; Amusan, OT; Arowosegbe, MA; Bello, AO; Ishola, PG; Kanmodi, RI; Lugbe, NE; Obasieke, PE; Ogun, SO; Ogungbe, BF; Ogunleye, AJ; Ogunmola, OJ; Omotuyi, OI; Oyende, FO; Saibu, GM1
Barriga, S; Burdaeva, O; Conte, P; Frenzel, M; Grischke, EM; Hurt, K; Inoue, K; Johnston, S; Kaufman, PA; Koh, H; Llombart-Cussac, A; Lu, Y; Masuda, N; Neven, P; Okera, M; Pivot, X; Sledge, GW; Sohn, J; Toi, M1
Chen, F; Li, T; Wang, Q; Wang, Y; Xiong, Y; Yu, X; Zeng, Y; Zhou, F; Zhou, Y1
Eismann, J; Gray, KP; Heng, YJ; Konstantinopoulos, PA; Matulonis, UA; Murphy, CJ; Nabavi, S; Vlachos, IS; Waldschmidt, JM; Wulf, GM1
Cai, L; Cordover, E; Gionco, J; Jacinto, E; Kong, AN; Minden, A; Patel, C; Sargsyan, D; Shan, NL; Wei, J; Wu, R1
Arteaga, CL; Barroso-Sousa, R; Bermejo, B; Cantley, LC; Céliz, P; Ciruelos, E; Garrido-Castro, AC; Gavilá, J; Guo, H; Krop, IE; Li, Y; Lin, NU; Mills, GB; Paré, L; Prat, A; Rodon, J; Saura, C; Savoie, J; Serra, V; Solit, DB; Villagrasa, P; Winer, EP; Xu, Z1
Ge, Y; He, G; Li, H; Wang, J; Wang, S; Xu, Y; Zhu, Q1
Chen, L; Li, Y; Wang, S; Wang, X; Wang, Y; Zhang, W1
Bilbao, D; Camarena, V; Kesmodel, SB; Mustafi, S; Qureshi, R; Sant, DW; Slingerland, J; Wang, G; Wilkes, Z1
Inoue, K; Ito, Y; Iwata, H; Kawaguchi, T; Llombart-Cussac, A; Masuda, N; Miyoshi, Y; Mori, J; Mukai, H; Nakayama, T; Sakaguchi, S; Sledge, GW; Takahashi, M; Tanizawa, Y; Toi, M; van der Walt, JS1
Guney Eskiler, G; Ozman, Z; Sekeroglu, MR1
Hu, Q; Kong, L; Qin, X; Tu, J; Tu, K; Wang, Y; Yang, C; Yang, T; Yu, Y; Zhang, Z1
Banskota, S; Gautam, J; Jeon, YH; Jeong, BS; Kim, JA; Lee, H; Lee, YJ1
Hu, Y; Yang, Q; Zhang, J; Zhao, H1
Birge, RB; Calianese, D; Davra, V; De Lorenzo, MS; Geng, K; Kasikara, C; Kotenko, SV; Quigley, M; Spires, TE; Sriram, G; Suarez-Lopez, L; Wichroski, M; Yaffe, MB1
Han, ES; Mortimer, J; Wen, W; Xing, Q; Yan, J; Yim, JH; Yost, SE; Yuan, Y1
Bai, X; Han, G; He, Q; Jiang, H1
Choi, HJ; Choi, JW; Jang, KS; Kang, JH; Kim, HY; Kim, S; Kong, G; Lee, JY; Oh, SH; Oh, YH; Park, JH; Shin, DH; Son, T; Won, HY; Woo, JK; Yi, K1
Hu, Y; Zhang, J; Zhang, M; Zhou, Y1
Bai, J; Guo, R; Hu, Y; Yu, F; Zhang, H; Zhang, J; Zhang, S; Zhao, J; Zhou, Y1
Asara, JM; Bellinger, G; Cantley, LC; Daly, MB; Hok, RC; Hu, H; Juvekar, A; Kim, B; Lien, EC; Lyssiotis, CA; Scully, R; Seth, P; Son, J; Ullas, S; Wulf, GM; Yadegarynia, S1
Chen, S; Ma, WJ; Wu, XZ; Zhang, HR; Zhang, JH; Zhang, WL1
Baloglu, E; Crochiere, M; Das-Gupta, S; Landesman, Y; Minden, A; Rane, C; Senapedis, W1

Reviews

1 review(s) available for alpha-aminopyridine and Triple Negative Breast Neoplasms

ArticleYear
Cyclin-Dependent Kinase 4/6 Inhibitors for Treatment of Hormone Receptor-Positive, ERBB2-Negative Breast Cancer: A Review.
    JAMA oncology, 2023, 09-01, Volume: 9, Issue:9

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Protein Kinase Inhibitors; Receptor, ErbB-2; Triple Negative Breast Neoplasms

2023

Trials

4 trial(s) available for alpha-aminopyridine and Triple Negative Breast Neoplasms

ArticleYear
Phase II study of chidamide in combination with cisplatin in patients with metastatic triple-negative breast cancer.
    Annals of palliative medicine, 2021, Volume: 10, Issue:11

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cisplatin; Female; Humans; Treatment Outcome; Triple Negative Breast Neoplasms

2021
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.
    JAMA oncology, 2020, Jan-01, Volume: 6, Issue:1

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Fulvestrant; Humans; Middle Aged; Receptor, ErbB-2; Triple Negative Breast Neoplasms

2020
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer.
    Breast cancer research : BCR, 2020, 11-02, Volume: 22, Issue:1

    Topics: Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Class I Phosphatidylinositol 3-Kinases; Disease Progression; Female; High-Throughput Nucleotide Sequencing; Humans; Middle Aged; Morpholines; Neoplasm Metastasis; Patient Safety; Protein Kinase Inhibitors; Proteomics; Response Evaluation Criteria in Solid Tumors; Survival Rate; Treatment Outcome; Triple Negative Breast Neoplasms

2020
Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy.
    Breast cancer (Tokyo, Japan), 2021, Volume: 28, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Double-Blind Method; Female; Fulvestrant; Humans; Japan; Middle Aged; Quality of Life; Receptor, ErbB-2; Triple Negative Breast Neoplasms

2021

Other Studies

21 other study(ies) available for alpha-aminopyridine and Triple Negative Breast Neoplasms

ArticleYear
A novel ribociclib derivative WXJ-103 exerts anti-breast cancer effect through CDK4/6.
    Anti-cancer drugs, 2023, 08-01, Volume: 34, Issue:7

    Topics: Aminopyridines; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 4; Humans; Purines; Triple Negative Breast Neoplasms

2023
Kaempferol as a Potential PAK4 Inhibitor in Triple Negative Breast Cancer: Extra Precision Glide Docking and Free Energy Calculation.
    Current drug discovery technologies, 2020, Volume: 17, Issue:5

    Topics: Acrylamides; Aminopyridines; Catalytic Domain; Female; Humans; Kaempferols; Molecular Docking Simulation; p21-Activated Kinases; Protein Kinase Inhibitors; Triple Negative Breast Neoplasms

2020
Ribociclib (LEE011) suppresses cell proliferation and induces apoptosis of MDA-MB-231 by inhibiting CDK4/6-cyclin D-Rb-E2F pathway.
    Artificial cells, nanomedicine, and biotechnology, 2019, Volume: 47, Issue:1

    Topics: Aminopyridines; Animals; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Cyclin-Dependent Kinase Inhibitor Proteins; E2F1 Transcription Factor; Female; Humans; Male; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Phosphorylation; Purines; Retinoblastoma Protein; Triple Negative Breast Neoplasms; Tumor Burden

2019
Transcriptome analysis reveals overlap in fusion genes in a phase I clinical cohort of TNBC and HGSOC patients treated with buparlisib and olaparib.
    Journal of cancer research and clinical oncology, 2020, Volume: 146, Issue:2

    Topics: Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Cystadenocarcinoma, Serous; Female; Forkhead Transcription Factors; Gene Expression Profiling; Gene Fusion; Humans; Middle Aged; Morpholines; Ovarian Neoplasms; Phthalazines; Piperazines; Repressor Proteins; RNA-Seq; Triple Negative Breast Neoplasms

2020
KPT-9274, an Inhibitor of PAK4 and NAMPT, Leads to Downregulation of mTORC2 in Triple Negative Breast Cancer Cells.
    Chemical research in toxicology, 2020, 02-17, Volume: 33, Issue:2

    Topics: Acrylamides; Aminopyridines; Antineoplastic Agents; Cell Proliferation; Cytokines; Down-Regulation; Drug Screening Assays, Antitumor; Female; Humans; Mechanistic Target of Rapamycin Complex 2; Nicotinamide Phosphoribosyltransferase; p21-Activated Kinases; Triple Negative Breast Neoplasms; Tumor Cells, Cultured

2020
Discovery of novel PARP/PI3K dual inhibitors with high efficiency against BRCA-proficient triple negative breast cancer.
    European journal of medicinal chemistry, 2021, Mar-05, Volume: 213

    Topics: Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Male; Mice; Mice, Inbred BALB C; Models, Molecular; Molecular Docking Simulation; Molecular Targeted Therapy; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Protein Binding; Solubility; Structure-Activity Relationship; Triple Negative Breast Neoplasms

2021
BKM120 sensitizes BRCA-proficient triple negative breast cancer cells to olaparib through regulating FOXM1 and Exo1 expression.
    Scientific reports, 2021, 02-26, Volume: 11, Issue:1

    Topics: Aminopyridines; Antineoplastic Agents; BRCA1 Protein; BRCA2 Protein; Cell Line, Tumor; DNA Repair Enzymes; Exodeoxyribonucleases; Female; Forkhead Box Protein M1; Gene Expression Regulation, Neoplastic; Humans; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Phthalazines; Piperazines; Triple Negative Breast Neoplasms

2021
Vitamin C sensitizes triple negative breast cancer to PI3K inhibition therapy.
    Theranostics, 2021, Volume: 11, Issue:8

    Topics: Aminopyridines; Animals; Apoptosis; Ascorbic Acid; Cell Line, Tumor; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Histone Code; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Molecular Targeted Therapy; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Precision Medicine; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays

2021
In vitro therapeutic effects of abemaciclib on triple-negative breast cancer cells.
    Journal of biochemical and molecular toxicology, 2021, Volume: 35, Issue:9

    Topics: Aminopyridines; Apoptosis; Autophagy; Benzimidazoles; Cell Line, Tumor; Female; G1 Phase Cell Cycle Checkpoints; Humans; Neoplasm Proteins; Resting Phase, Cell Cycle; Triple Negative Breast Neoplasms

2021
Combination of Chidamide-Mediated Epigenetic Modulation with Immunotherapy: Boosting Tumor Immunogenicity and Response to PD-1/PD-L1 Blockade.
    ACS applied materials & interfaces, 2021, Aug-25, Volume: 13, Issue:33

    Topics: Acetamides; Aminopyridines; Animals; Antineoplastic Agents; Benzamides; Biocompatible Materials; Cell Line, Tumor; Combined Modality Therapy; Drug Carriers; Drug Liberation; Epigenesis, Genetic; Female; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Liposomes; Mice; Mice, Inbred BALB C; Pyridines; Small Molecule Libraries; Tissue Distribution; Treatment Outcome; Triple Negative Breast Neoplasms

2021
Down-regulation of cathepsin S and matrix metalloproteinase-9 via Src, a non-receptor tyrosine kinase, suppresses triple-negative breast cancer growth and metastasis.
    Experimental & molecular medicine, 2018, 09-05, Volume: 50, Issue:9

    Topics: Aminopyridines; Animals; Cathepsins; Cell Proliferation; Cell Survival; Chickens; Chorioallantoic Membrane; Down-Regulation; Female; Humans; Matrix Metalloproteinase 9; MCF-7 Cells; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Signal Transduction; src-Family Kinases; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays

2018
Antitumor effects and mechanisms of olaparib in combination with carboplatin and BKM120 on human triple‑negative breast cancer cells.
    Oncology reports, 2018, Volume: 40, Issue:6

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA End-Joining Repair; DNA Repair; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Morpholines; Phthalazines; Piperazines; Triple Negative Breast Neoplasms

2018
Pan-TAM Tyrosine Kinase Inhibitor BMS-777607 Enhances Anti-PD-1 mAb Efficacy in a Murine Model of Triple-Negative Breast Cancer.
    Cancer research, 2019, 05-15, Volume: 79, Issue:10

    Topics: Aminopyridines; Animals; Antibodies, Monoclonal; Cell Line, Tumor; Disease Models, Animal; Female; Lymphocytes, Tumor-Infiltrating; Mice; Mice, Inbred C57BL; Programmed Cell Death 1 Receptor; Protein-Tyrosine Kinases; Pyridones; Triple Negative Breast Neoplasms; Tumor Microenvironment; Xenograft Model Antitumor Assays

2019
Combination therapy with BYL719 and LEE011 is synergistic and causes a greater suppression of p-S6 in triple negative breast cancer.
    Scientific reports, 2019, 05-17, Volume: 9, Issue:1

    Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Survival; Class I Phosphatidylinositol 3-Kinases; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Synergism; Enzyme Inhibitors; Female; Humans; Mice; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Purines; Retinoblastoma Protein; Ribosomal Protein S6 Kinases; Signal Transduction; Thiazoles; TOR Serine-Threonine Kinases; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays

2019
Chidamide suppresses the glycolysis of triple negative breast cancer cells partially by targeting the miR‑33a‑5p‑LDHA axis.
    Molecular medicine reports, 2019, Volume: 20, Issue:2

    Topics: Aminopyridines; Benzamides; Cell Line, Tumor; Cell Movement; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Glycolysis; Humans; L-Lactate Dehydrogenase; MicroRNAs; Signal Transduction; Triple Negative Breast Neoplasms

2019
MEL-18 loss mediates estrogen receptor-α downregulation and hormone independence.
    The Journal of clinical investigation, 2015, Volume: 125, Issue:5

    Topics: Aminopyridines; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Cysteine Endopeptidases; Drug Resistance, Neoplasm; Endopeptidases; Estrogen Receptor alpha; Estrogens; Female; Humans; Kaplan-Meier Estimate; Mice; Morpholines; Neoplasm Proteins; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Polycomb Repressive Complex 1; Progesterone; Proportional Hazards Models; Proteasome Endopeptidase Complex; Protein Processing, Post-Translational; Receptor, ErbB-2; Receptors, Progesterone; RNA, Messenger; RNA, Neoplasm; Sp1 Transcription Factor; Sumoylation; Tamoxifen; Triple Negative Breast Neoplasms; Tumor Suppressor Protein p53

2015
[Effects of NVP-BKM120 on the triple-negative breast cancer cell].
    Zhonghua yi xue za zhi, 2015, Volume: 95, Issue:40

    Topics: Aminopyridines; Animals; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Mice; Mice, Inbred BALB C; Mice, Nude; Morpholines; Triple Negative Breast Neoplasms

2015
The combination of NVP-BKM120 with trastuzumab or RAD001 synergistically inhibits the growth of breast cancer stem cells in vivo.
    Oncology reports, 2016, Volume: 36, Issue:1

    Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; MCF-7 Cells; Mice; Mice, Nude; Morpholines; Neoplastic Stem Cells; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Signal Transduction; Trastuzumab; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays

2016
Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion.
    Proceedings of the National Academy of Sciences of the United States of America, 2016, 07-26, Volume: 113, Issue:30

    Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; DNA Damage; DNA, Neoplasm; Female; Humans; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Morpholines; Nucleosides; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Poly(ADP-ribose) Polymerase Inhibitors; Triple Negative Breast Neoplasms

2016
[Molecular mechanisms of resistance to phosphatidyl inositol 3-kinase inhibitors in triple-negative breast cancer cells].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2016, Volume: 38, Issue:8

    Topics: Adaptor Proteins, Signal Transducing; Aminopyridines; Animals; beta Catenin; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Imidazoles; Mice; Morpholines; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phosphoproteins; Proto-Oncogene Proteins c-akt; Quinolines; Signal Transduction; TOR Serine-Threonine Kinases; Triple Negative Breast Neoplasms

2016
A novel orally bioavailable compound KPT-9274 inhibits PAK4, and blocks triple negative breast cancer tumor growth.
    Scientific reports, 2017, 02-15, Volume: 7

    Topics: Acrylamides; Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Disease Models, Animal; Female; Humans; Mice; p21-Activated Kinases; Phosphorylation; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays

2017